Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Association of Inflammatory Markers (ICC, MCVL) With Anti PD-1 Antibody Nivolumab Response: Evaluating Biomarkers for Predicting Immunotherapy Success in Patients With Metastatic Renal Cell Carcinoma

NCT06607809 is registered in ClinicalTrials.gov with Dr. Lutfi Kirdar Kartal Training and Research Hospital as lead sponsor.

NCT NCT06607809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06607809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Association of Inflammatory Markers (ICC, MCVL) With Anti PD-1 Antibody Nivolumab Response: Evaluating Biomarkers for Predicting Immunotherapy Success in Patients With Metastatic Renal Cell Carcinoma
Lead sponsor
Dr. Lutfi Kirdar Kartal Training and Research Hospital
Phase
Observational
Overall status
Completed
Start date
February 1, 2022
Completion date
January 1, 2024
Enrollment
99 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma